DiaMedica Announces that Co-Administration of DM-199 with Insulin Enhances Insulin’s Glucose Lowering Activity
16-Oct-2012 (Minneapolis, MN)
DiaMedica (TSX-V:DMA) is pleased to report that DM-199 has demonstrated a statistically significant effect in lowering daily insulin needs when co-administered with basal long-acting insulin (Lantus®) in a pre-clinical diabetes study. Full results to be published.
The study confirmed DM-199 alone lowers fasting glucose values (p=0.000003) in a diabetic model. During an oral glucose tolerance test, DM-199 co-administered with basal long-acting insulin significantly reduced the spike in glucose levels immediately and well after a meal to near normal levels (p=0.00002), as measured by area under the curve glucose, with no evidence of hypoglycemia.
“The results from this study suggest DM-199 co-administered with basal long-acting insulin may reduce the need for short-acting insulin around meals while improving glucose control in diabetic patients,” stated Rick Pauls, Chairman & CEO of DiaMedica. “Lowering the frequency and amount of daily insulin injections and reducing the risk of hypoglycemia could significantly improve the quality of life for Type 1 diabetics and possibly for Type 2 diabetics. Results are to be confirmed in future human studies.”
“These promising results further suggest the potential of DM-199 for the treatment of Type 1 diabetes,” stated Dr. Alexei Savinov, Associate Scientist at The Sanford Project who performed the study. The Sanford Project is an emerging translational research center focused on targeted diabetes research, cures and care. “Earlier pre-clinical studies have also independently demonstrated the ability of the DM-199 program to lower glucose levels, significantly halt the autoimmune attack and proliferate insulin-producing beta cells.”
+ Back to All News
About DiaMedica
DiaMedica Inc. (TSX-V:DMA) is a biotechnology company developing first-in-class treatments for the treatment of diabetes. DiaMedica's lead compound, DM-199, is a recombinant human protein for the treatment of both Type 1 and Type 2 diabetes and their complications. The Company is also developing the first therapeutic GPCR agonist monoclonal antibody, DM-204, for the treatment of Type 2 diabetes and cardiovascular disease. DiaMedica’s shares trade on the Toronto Stock Exchange Venture (TSXV: DMA). For more information please visit www.diamedica.com.
For further information please contact:
Rick Pauls
Chairman & CEO
DiaMedica Inc.
Phone: 763-710-4455
Email: info@diamedica.com
Forward-Looking Statements
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica’s expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this News Release.